CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study

Not Applicable

Recruiting

• Conditions: Tricuspid Valve Disease; Tricuspid Valve Insufficiency
• Interventions: Device: Tricuspid valve replacement with the Cor TRICUSPID ECM Valve

• Registration Number: NCT05742906
• Lead Sponsor: CorMatrix Cardiovascular, Inc.

Brief Summary

The goal of this pivotal study is to demonstrate the safety and performance of the Cor TRICUSPID ECM (extracellular matrix) Valve (or Cor PEDIATRIC Tricuspid ECM Valve) for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric patients. The main question(s) it aims to answer are:

* whether the device may be implanted successfully and safely, and

* whether the device effectively treats tricuspid valve disease and dysfunction through 12 months

Participants will undergo:

* preoperative evaluation

* tricuspid valve replacement with the Cor TRICUSPID ECM Valve

* postoperative evaluation, including at hospital discharge, 30 days, 6 months, and 12 months, and then annually thereafter through 5 years

Detailed Description

CorMatrix Cardiovascular, Inc. has developed a device for heart valve replacement, the Cor TRICUSPID ECM Valve for adults and the Cor PEDIATRIC Tricuspid ECM Valve for pediatrics (collectively these devices will be referred to as the Cor TRICUSPID ECM Valve(s)), which can be implanted to replace dysfunctional tricuspid heart valves. The objective of this Pivotal Study is to collect safety and effectiveness data on surgical tricuspid valve replacement procedures using the Cor TRICUSPID ECM valve to support a Humanitarian Device Exemption (HDE) marketing application.

Because the majority of tricuspid valve replacements (TVRs) (approximately 80%) are performed concomitantly with other cardiac operations, including replacements of mitral or aortic valves, it is anticipated that a portion of study subjects will require concomitant replacement or repair of a dysfunctional mitral or aortic valve, based on the clinical judgment of the investigator.

Therefore, safety with the Cor TRICUSPID ECM Valve will be established by Procedural, Technical and Device Success.

Study Timeline

• Study Start: 2022-08-10
• Study First Submitted: 2023-01-30
• Study First Submitted QC: 2023-02-14
• Study First Posted: 2023-02-24
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-14
• Last Update Posted: 2024-03-18
• Primary Completion: 2024-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 92

Inclusion Criteria

1. Patient with a regurgitant or absent tricuspid valve requiring surgical treatment including those patients having concomitant cardiac procedures
2. Patient/authorized legal guardian understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provides written informed consent and the pediatric patient (if applicable) provides written assent (if able) prior to procedure
3. Patient/patient's authorized legal guardian is geographically stable (or willing to return for required study follow-up) and understands and is willing to fulfill all of the expected requirements of this clinical protocol
4. Patients where the Cor TRICUSPID ECM Valve will be the physiological right-sided atrioventricular (AV) valve

Exclusion Criteria

1. Tricuspid annulus too small (< 10mm) to accommodate the Cor TRICUSPID ECM Valve
2. Left ventricular ejection fraction (LVEF) < 25%
3. Mean pulmonary pressure ≥ 50mmHg or pulmonary vascular resistance greater than 6 Woods Units
4. Emergency cardiac procedure. An example would be a person requiring resuscitation and in cardiogenic shock. An unscheduled or unplanned emergency surgery
5. Cardiac transplant patient
6. Acute transmural myocardial infarction (MI) within 7 days of enrollment that results in cardiogenic shock
7. Patients with a single ventricle where the Cor TRICUSPID ECM Valve would be the systemic AV valve
8. Documented primary coagulopathy or uncorrected platelet disorder, including thrombocytopenia (absolute platelet count < 30k). Patient can be enrolled regardless of these parameters if in the opinion of the Investigating Surgeon the coagulopathy can be adequately reversed by transfusions. An example would be the reversal of thrombocytopenia by transfusion of platelets
9. Documented evidence of intrinsic hepatic disease (defined as liver enzyme values (aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin) that are > 5 times the upper limit of reference range within 30 days of enrollment, except in association with acute/reversible decompensation as determined by the Investigator)
10. Documented evidence of significant renal dysfunction (serum creatinine > 4.0mg/dl or GFR< 30 on the modified Schwartz formula)
11. Stroke within 30 days prior to enrollment
12. Major or progressive non-cardiac disease (liver failure, renal failure, cancer (CA)) that has a life expectancy of less than one year
13. Known cancer (cancer-free ≤ 1 year; does not include non-metastatic basal cell carcinoma or cervical carcinoma) and/or undergoing treatment including chemotherapy and radiotherapy
14. Hematological disorders (e.g., aplastic anemia) or patients taking bone marrow suppressant drugs
15. Known sensitivity to porcine materials
16. Contraindication to anticoagulation/antiplatelet therapy (aspirin (ASA) and/or Plavix)
17. Patients who are pregnant (method of assessment Investigator's discretion)
18. Patients who are currently enrolled in another investigational study or registry that would directly impact the treatment or outcome of the current study, without CorMatrix written approval

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A: Adults treated with SIS 1.0 Cor TRICUSPID ECM Valve	Tricuspid valve replacement with the Cor TRICUSPID ECM Valve	Adults (\>/= 21 years of age) treated with the SIS 1.0 Cor TRICUSPID ECM Valve
Group B: Pediatrics treated with SIS 1.0 Cor TRICUSPID ECM Valve	Tricuspid valve replacement with the Cor TRICUSPID ECM Valve	Pediatrics (\<21 years of age) treated with SIS 1.0 Cor TRICUSPID ECM Valve
Group D: Pediatrics treated with SIS 2.0 Cor TRICUSPID ECM Valve	Tricuspid valve replacement with the Cor TRICUSPID ECM Valve	Pediatrics (\<21 years of age) treated with SIS 2.0 Cor TRICUSPID ECM Valve
Group C: Adults treated with SIS 2.0 Cor TRICUSPID ECM Valve	Tricuspid valve replacement with the Cor TRICUSPID ECM Valve	Adults (\>/= 21 years of age) treated with the SIS 2.0 Cor TRICUSPID ECM Valve

Primary Outcome Measures

Name	Time	Method
Safety Outcome - Procedural Success	30 days	Device Success and no tricuspid valve device-related Serious Adverse Events (SAEs)
Effectiveness Outcome - Individual Patient Success	12 months	* Device success and; * no Cor TRICUSPID ECM Valve-related re-hospitalizations or re-interventions of the Cor TRICUSPID ECM Valve (clinically significant: new endocarditis of the tricuspid valve \[TV\], recurrence of tricuspid regurgitation \[TR\] \> moderate, or right sided heart failure \[HF\]) unless endocarditis is secondary to recurrent drug abuse.; * Improvement vs. baseline in symptoms (improvement in New York Heart Association \[NYHA\] \[adult subjects\] and clinical improvement \[pediatric subjects\] Class \>/= 1 grade)

Trial Locations

Locations (2)

Columbia University Irving Medical Center/New York Presbyterian; 🇺🇸 New York, New York, United States

St Francis Hospital; 🇺🇸 Indianapolis, Indiana, United States